Suppr超能文献

当前及未来口服去氨加压素剂型的潜在临床应用(综述)

Potential clinical applications of current and future oral forms of desmopressin (Review).

作者信息

Everaert Karel, Holm-Larsen Tove, Bou Kheir George, Rottey Sylvie, Weiss Jeffrey P, Vande Walle Johan, Kabarriti Abdo E, Dossche Lien, Hervé François, Spinoit Anne-Françoise, Nørgaard Jens Peter, Juul Kristian Vinter

机构信息

Faculty of Medicine and Health Sciences, Department of Human Structure and Repair, Ghent University Hospital, 9000 Ghent, Belgium.

Department of Urology, Ghent University Hospital, 9000 Ghent, Belgium.

出版信息

Exp Ther Med. 2024 May 29;28(2):303. doi: 10.3892/etm.2024.12592. eCollection 2024 Aug.

Abstract

Desmopressin is a synthetic analogue of vasopressin and a selective vasopressin receptor 2 agonist. It was first synthesised in 1967 and utilised for its antidiuretic properties. It is also used in bleeding disorders to enhance clotting. Other potential uses of the drug have been reported. The present review aims to provide a broad overview of the literature on potential further uses of oral forms of desmopressin. Key therapeutic areas of interest were identified based on known physiological activities/targets of desmopressin or reports of an effect of desmopressin in the literature. The feasibility of adequate dosing with oral forms of the drug was also considered. Systematic literature searches were carried out using the silvi.ai software for the identified areas, and summaries of available papers were included in tables and discussed. The results of the searches showed that desmopressin has been investigated for its efficacy in a number of areas, including bleeding control, renal colic, the central nervous system and oncology. Evidence suggests that oral desmopressin may have the potential to be of clinical benefit for renal colic and bleeding control in particular. However, further research is needed to clarify its effect in these areas, including randomised controlled studies and studies specifically of oral formulations (and doses). Further research may also yield findings for cancer, cognition and overactive bladder.

摘要

去氨加压素是血管加压素的合成类似物,也是一种选择性血管加压素2受体激动剂。它于1967年首次合成,并因其抗利尿特性而被使用。它还用于出血性疾病以增强凝血。该药物的其他潜在用途也有报道。本综述旨在对口服去氨加压素潜在进一步用途的文献进行全面概述。基于去氨加压素已知的生理活性/靶点或文献中关于去氨加压素作用的报道,确定了感兴趣的关键治疗领域。还考虑了使用该药物口服剂型进行适当给药的可行性。使用silvi.ai软件对确定的领域进行了系统的文献检索,可用论文的摘要被列入表格并进行了讨论。检索结果表明,已对去氨加压素在多个领域的疗效进行了研究,包括出血控制、肾绞痛、中枢神经系统和肿瘤学。有证据表明,口服去氨加压素尤其可能对肾绞痛和出血控制具有临床益处。然而,需要进一步研究以阐明其在这些领域的作用,包括随机对照研究和专门针对口服制剂(和剂量)的研究。进一步的研究也可能在癌症、认知和膀胱过度活动症方面取得成果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dfe/11170333/677ef5b795bd/etm-28-02-12592-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验